Synthetic glucocorticoid tablets .
Package containing 1 blister with 10 tablets.
Display with 30 blisters with 10 tablets each.
Synthetic non-fluorinated glucocorticoid 4 times stronger than cortisol, but with an almost non-existing mineralocorticoid effect:
Anti-inflammatory.
Antipruritic.
Antiallergic.
Immunosuppressant
.
Inflammatory and allergic processes (pruritus) for which the use of Glucocorticoids is indicated.
Autoimmune diseases.
As coadjuvant in antineoplastic therapy.
Replacement therapy.
Each tablet contains:
Prednisolone 20 mg
Excipients q.s.
Dogs and cats: Replacement therapy: 0.25 mg/kg/day.
In stressful conditions, increase the dose 2-5 times.
Autoimmune diseases and as coadjuvant in antineoplastic therapy: 2-4 mg/kg/day.In inflammatory processes: 0.5-1 mg/kg/day.
For prolonged treatments, the therapy should be administered in alternate days. This scheme avoids the hypothalamic-pituitary-adrenal axis suppression, allowing for its recovery on the days when the prednisolone is not administered.
1) Induction dose 0.5-1 mg/kg/12 h for 5-7 days.
2) Continue with 1-2 mg/kg once a day every 48 h for 7 days.
3) Continue with the same administration regimen (every 48 h) but lower the dose by 50% for 7 days.
4) Reduce the amount of Prednisolone on a weekly basis (but always on alternate days) up to a minimum maintenance dose that provides the desired therapeutic effect.
5) The drug administration should not be interrupted abruptly but gradually.
Suggested treatment scheme.
Bacterial, viral, and fungal infectious diseases. Demodectic mange. Gastrointestinal ulcers.Ulcerative colitis. Pancreatitis. Renal failure.Amyloidosis. Diabetes mellitus. Osteoporosis. Chronic erosive arthritis. Pregnancy.
Polyuria. Polydipsia. Polyphagia. Euphoria.
Pregnancy and lactation.
An indiscriminate, long-term, high-dose therapy results in Cushing syndrome (iatrogenic hyperadrenocorticism) concomitant with a secondary adrenal insufficiency. A sudden interruption in the administration of glucocorticoids can cause Addison syndrome (hypoadrenocorticism) secondary to underfunctioning of the hypothalamic-pituitary-adrenal axis.